JP2016538292A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016538292A5 JP2016538292A5 JP2016530991A JP2016530991A JP2016538292A5 JP 2016538292 A5 JP2016538292 A5 JP 2016538292A5 JP 2016530991 A JP2016530991 A JP 2016530991A JP 2016530991 A JP2016530991 A JP 2016530991A JP 2016538292 A5 JP2016538292 A5 JP 2016538292A5
- Authority
- JP
- Japan
- Prior art keywords
- implant
- biodegradable
- bioerodible
- plga
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007943 implant Substances 0.000 claims description 25
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 8
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims description 5
- 201000011190 diabetic macular edema Diseases 0.000 claims description 5
- 229920002988 biodegradable polymer Polymers 0.000 claims description 4
- 239000004621 biodegradable polymer Substances 0.000 claims description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 4
- 229960003957 dexamethasone Drugs 0.000 claims description 4
- 230000002209 hydrophobic effect Effects 0.000 claims description 4
- 239000011159 matrix material Substances 0.000 claims description 3
- 238000002513 implantation Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 241000282412 Homo Species 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000013543 active substance Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 2
- 208000001344 Macular Edema Diseases 0.000 description 1
- 206010025415 Macular oedema Diseases 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 201000010230 macular retinal edema Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361904887P | 2013-11-15 | 2013-11-15 | |
| US61/904,887 | 2013-11-15 | ||
| PCT/US2014/065804 WO2015073895A1 (en) | 2013-11-15 | 2014-11-14 | Methods of treatment of ocular conditions with a sustained drug delivery implant |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019225503A Division JP7022735B2 (ja) | 2013-11-15 | 2019-12-13 | 持続的薬物送達インプラントによる眼の状態の治療の方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016538292A JP2016538292A (ja) | 2016-12-08 |
| JP2016538292A5 true JP2016538292A5 (enExample) | 2019-06-20 |
| JP6675307B2 JP6675307B2 (ja) | 2020-04-01 |
Family
ID=52001114
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016530991A Active JP6675307B2 (ja) | 2013-11-15 | 2014-11-14 | 持続的薬物送達インプラントによる眼の状態の治療の方法 |
| JP2019225503A Active JP7022735B2 (ja) | 2013-11-15 | 2019-12-13 | 持続的薬物送達インプラントによる眼の状態の治療の方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019225503A Active JP7022735B2 (ja) | 2013-11-15 | 2019-12-13 | 持続的薬物送達インプラントによる眼の状態の治療の方法 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20150140062A1 (enExample) |
| EP (2) | EP3714875A1 (enExample) |
| JP (2) | JP6675307B2 (enExample) |
| KR (3) | KR20220082934A (enExample) |
| CN (1) | CN105764517A (enExample) |
| AU (4) | AU2014348369B2 (enExample) |
| CA (1) | CA2929689A1 (enExample) |
| CL (1) | CL2016001167A1 (enExample) |
| CY (1) | CY1123344T1 (enExample) |
| DK (1) | DK3068403T3 (enExample) |
| ES (1) | ES2819215T5 (enExample) |
| HU (1) | HUE050913T2 (enExample) |
| IL (2) | IL245548A0 (enExample) |
| MX (2) | MX2016006334A (enExample) |
| MY (1) | MY176039A (enExample) |
| NZ (1) | NZ719953A (enExample) |
| PH (1) | PH12016500869B1 (enExample) |
| PL (1) | PL3068403T3 (enExample) |
| PT (1) | PT3068403T (enExample) |
| RU (1) | RU2690841C1 (enExample) |
| SG (1) | SG10201809363SA (enExample) |
| SI (1) | SI3068403T1 (enExample) |
| UA (1) | UA122117C2 (enExample) |
| WO (1) | WO2015073895A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115337254A (zh) * | 2015-07-23 | 2022-11-15 | 爱瑞制药公司 | 用于治疗眼病的玻璃体内药物递送系统 |
| AU2017321980B2 (en) | 2016-09-02 | 2020-04-30 | Alcon Inc. | Implant applicators |
| CA3087238A1 (en) | 2018-05-24 | 2019-11-28 | Celanese EVA Performance Polymers Corporation | Implantable device for sustained release of a macromolecular drug compound |
| EP3803866A4 (en) | 2018-05-24 | 2022-03-16 | Nureva Inc. | METHOD, APPARATUS, AND COMPUTER READABLE MATERIALS FOR MANAGING SEMI-CONSTANT (PERSISTENT) SOUND SOURCES IN MICROPHONE CATCH/HOME AREAS |
| CN111989068B (zh) | 2018-05-24 | 2024-10-25 | 塞拉尼斯伊娃高性能聚合物公司 | 用于持续释放大分子药物化合物的可植入器件 |
| PE20240329A1 (es) | 2019-06-05 | 2024-02-27 | Regeneron Pharma | Dispositivos y metodos para administracion de dosis de precision |
| CN116133664A (zh) * | 2020-07-16 | 2023-05-16 | 视觉治疗股份有限公司 | 含有糖皮质激素的眼部插入物 |
| EP4329734A4 (en) | 2021-04-26 | 2025-04-02 | Celanese EVA Performance Polymers LLC | Implantable device for the delayed release of a macromolecular drug compound |
| US12649031B2 (en) | 2021-09-08 | 2026-06-09 | Regeneron Pharmaceuticals, Inc. | Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6726918B1 (en) | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
| US6699493B2 (en) | 2000-11-29 | 2004-03-02 | Oculex Pharmaceuticals, Inc. | Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
| US20050048099A1 (en) * | 2003-01-09 | 2005-03-03 | Allergan, Inc. | Ocular implant made by a double extrusion process |
| US20050244469A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
| US8119154B2 (en) | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
| US8685435B2 (en) * | 2004-04-30 | 2014-04-01 | Allergan, Inc. | Extended release biodegradable ocular implants |
| US20050244500A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Intravitreal implants in conjuction with photodynamic therapy to improve vision |
| US20090082321A1 (en) * | 2007-09-21 | 2009-03-26 | Allergan, Inc. | Steroid containing drug delivery systems |
| AU2012214146A1 (en) * | 2011-02-11 | 2013-08-29 | Psivida Us, Inc. | Methods of treating macular edema using antiedema therapeutics |
-
2014
- 2014-11-14 WO PCT/US2014/065804 patent/WO2015073895A1/en not_active Ceased
- 2014-11-14 EP EP20173457.1A patent/EP3714875A1/en active Pending
- 2014-11-14 HU HUE14805768A patent/HUE050913T2/hu unknown
- 2014-11-14 DK DK14805768.0T patent/DK3068403T3/da active
- 2014-11-14 KR KR1020227018854A patent/KR20220082934A/ko not_active Ceased
- 2014-11-14 EP EP14805768.0A patent/EP3068403B2/en active Active
- 2014-11-14 CA CA2929689A patent/CA2929689A1/en active Pending
- 2014-11-14 RU RU2016119132A patent/RU2690841C1/ru active
- 2014-11-14 NZ NZ719953A patent/NZ719953A/en not_active IP Right Cessation
- 2014-11-14 AU AU2014348369A patent/AU2014348369B2/en active Active
- 2014-11-14 US US14/542,189 patent/US20150140062A1/en not_active Abandoned
- 2014-11-14 KR KR1020167015466A patent/KR102475746B1/ko active Active
- 2014-11-14 UA UAA201605224A patent/UA122117C2/uk unknown
- 2014-11-14 CN CN201480062403.7A patent/CN105764517A/zh active Pending
- 2014-11-14 PL PL14805768T patent/PL3068403T3/pl unknown
- 2014-11-14 JP JP2016530991A patent/JP6675307B2/ja active Active
- 2014-11-14 PT PT148057680T patent/PT3068403T/pt unknown
- 2014-11-14 SI SI201431652T patent/SI3068403T1/sl unknown
- 2014-11-14 SG SG10201809363SA patent/SG10201809363SA/en unknown
- 2014-11-14 MX MX2016006334A patent/MX2016006334A/es unknown
- 2014-11-14 ES ES14805768T patent/ES2819215T5/es active Active
- 2014-11-14 MY MYPI2016000899A patent/MY176039A/en unknown
- 2014-11-14 KR KR1020247013455A patent/KR20240058976A/ko not_active Ceased
-
2016
- 2016-05-09 IL IL245548A patent/IL245548A0/en unknown
- 2016-05-11 PH PH12016500869A patent/PH12016500869B1/en unknown
- 2016-05-13 CL CL2016001167A patent/CL2016001167A1/es unknown
- 2016-05-13 MX MX2022002306A patent/MX2022002306A/es unknown
-
2019
- 2019-12-13 JP JP2019225503A patent/JP7022735B2/ja active Active
-
2020
- 2020-06-30 AU AU2020204362A patent/AU2020204362A1/en not_active Abandoned
- 2020-09-14 CY CY20201100867T patent/CY1123344T1/el unknown
-
2022
- 2022-02-23 IL IL290837A patent/IL290837A/en unknown
- 2022-06-29 AU AU2022204607A patent/AU2022204607A1/en not_active Abandoned
-
2024
- 2024-08-09 AU AU2024205640A patent/AU2024205640B2/en active Active
-
2025
- 2025-02-21 US US19/060,301 patent/US20250319031A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240082150A1 (en) | Ocular compositions | |
| BRPI0510439A (pt) | implantes intraoculares de liberação sustentada contendo macromoléculas e métodos relacionados | |
| PH12017501097A1 (en) | Sunitinib formulations and methods for use thereof in treatment of ocular disorders | |
| WO2014165308A3 (en) | Microsphere drug delivery system for sustained intraocular release | |
| WO2016042163A3 (en) | Ophthalmic drug compositions | |
| BRPI0506983A (pt) | composições para terapia localizada dos olhos, compreendendo preferencialmente acetonida de triancinolona e ácido hialurÈnico | |
| CY1117357T1 (el) | Υγρες φαρμακοτεχνικες μορφες για θεραπεια ασθενειων ή καταστασεων | |
| RU2015134774A (ru) | Имплантат для пролонгированной доставки лекарственного средства | |
| JP2007535535A5 (enExample) | ||
| MX378707B (es) | Compuestos para el tratamiento de enfermedades y trastornos oftalmicos. | |
| EP3861982A3 (en) | Intracameral implant for treatment of an ocular condition | |
| JP2017537985A5 (enExample) | ||
| RU2016119132A (ru) | Способы лечения патологических состояний глаза с помощью имплантата с долговременной доставкой лекарственного вещества | |
| BR112015006929A2 (pt) | sistemas de distribuição de droga biodegradável para liberação sustentada de proteínas | |
| HK1252771A1 (zh) | 用於治疗眼部病状的玻璃体内药物递送系统 | |
| HRP20220922T1 (hr) | Usadive tablete naltreksona | |
| JP2017523983A5 (enExample) | ||
| WO2016060917A3 (en) | Formulations for histatin therapeutics | |
| HRP20250123T1 (hr) | Spojevi za liječenje bolesti vezanih s lipofuscinom | |
| BR112015011294A8 (pt) | nanopartículas com polímero biodegradável e biocompatível plga carregadas com o fármaco pentoxifilina de uso humano e uso destas | |
| JP2024167340A (ja) | コーティング眼用インプラント | |
| TH1601002766A (th) | วิธีการบำบัดอาการเจ็บป่วยซึ่งเกี่ยวกับตาด้วยสิ่งปลูกฝังสำหรับนำส่งยาแบบทยอย |